Combipatch and Application site hypersensitivity - a phase IV clinical study of FDA data

Summary:

Application site hypersensitivity is reported as a side effect among people who take Combipatch (estradiol; norethindrone acetate), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Klonopin, and have Hot flush.

The phase IV clinical study analyzes which people have Application site hypersensitivity when taking Combipatch. It is created by eHealthMe based on reports of 3,544 people who have side effects when taking Combipatch from the FDA, and is updated regularly.

What is Combipatch?

Combipatch has active ingredients of estradiol; norethindrone acetate. It is often used in menopause. eHealthMe is studying from 3,599 Combipatch users. Check the latest studies of Combipatch.

What is Application site hypersensitivity?

Application site hypersensitivity is found to be associated with 102 drugs and 283 conditions by eHealthMe. Check the latest studies of Application site hypersensitivity.

On Aug, 13, 2026

3,544 people reported to have side effects when taking Combipatch.
Among them, 42 people (1.19%) have Application site hypersensitivity.

Could Combipatch cause Application site hypersensitivity?

Among these 42 people:

How long have people been on Combipatch when they have Application site hypersensitivity? *

What is the gender of people who have Application site hypersensitivity when taking Combipatch? *

female: 100 %
male: 0.0 %

What is the age of people who have Application site hypersensitivity when taking Combipatch? *

What are other drugs people take besides Combipatch? *

What are other side effects people have besides Application site hypersensitivity? *

Application Site Erythema (redness of the skin at application site): 32 people, 76.19%
Application Site Pruritus (application site severe itching of the skin): 30 people, 71.43%
Application Site Irritation: 17 people, 40.48%
Application Site Urticaria: 14 people, 33.33%
Application Site Pain: 12 people, 28.57%
Application Site Swelling: 10 people, 23.81%
Hot Flush (sudden feelings of heat): 6 people, 14.29%
Application Site Rash: 6 people, 14.29%
High Blood Cholesterol: 4 people, 9.52%
Breast Pain: 3 people, 7.14%

What are the existing conditions these people have? *

Hot Flush (sudden feelings of heat): 23 people, 54.76%
Night Sweats (sweating in night): 13 people, 30.95%
Stress And Anxiety: 6 people, 14.29%
Sleep Disorder: 4 people, 9.52%
Osteoporosis (bones weak and more likely to break): 3 people, 7.14%
Vulvovaginal Dryness: 2 people, 4.76%
Fatigue (feeling of tiredness): 2 people, 4.76%
Postmenopause: 2 people, 4.76%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 2 people, 4.76%
Hypersensitivity: 2 people, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Combipatch and have Application site hypersensitivity?

- Check whether Application site hypersensitivity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Combipatch:

Combipatch (3,599 reports)

Application site hypersensitivity treatments and more:

Application site hypersensitivity (1,138 reports)

How severe was Application site hypersensitivity and when was it recovered:

Application site hypersensitivity in Combipatch

Expand to all the drugs that have ingredients of estradiol; norethindrone acetate:

Application site hypersensitivity and drugs with ingredients of estradiol; norethindrone acetate

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Combipatch:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Application site hypersensitivity:

Application site hypersensitivity (102 drugs)

Browse all the conditions that are associated with Application site hypersensitivity:

Application site hypersensitivity (283 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on estradiol; norethindrone acetate (the active ingredients of Combipatch) and Combipatch (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.